轻中度溃疡性结肠炎患者报告结局与黏膜炎症不一致
该研究为一项3期非劣效试验的事后分析,纳入817例接受美沙拉秦治疗的轻中度溃疡性结肠炎成人患者,评估直肠出血和排便频率与内镜缓解(Mayo内镜子评分MES 0/1)的关联。结果显示无直肠出血可识别内镜缓解,但许多缓解患者仍有排便频率增加,提示排便频率并非敏感的活动性标志。
要点
- 无直肠出血对识别内镜缓解有较好价值,但排便频率增加在缓解患者中常见。
- 排便频率不宜单独作为轻中度UC疾病活动度的敏感标志。
- 患者报告结局与黏膜炎症存在不一致,临床需结合内镜评估。
核心结论
- 在轻中度UC患者中,无直肠出血可识别内镜缓解,但许多缓解患者仍有排便频率增加,提示排便频率可能不是敏感的活动性标志。
研究设计与样本
- 3期非劣效试验的事后分析,纳入817例接受美沙拉秦治疗的轻中度UC成人患者,在第0、8、38周获取直肠出血、排便频率和MES。
主要发现
- 第8周MES为0的患者中,7/82(9%)直肠出血评分≥1,40/82(49%)排便频率评分≥1。
- 第38周MES为0的患者中,6/167(4%)直肠出血评分≥1,63/167(38%)排便频率评分≥1。
- 第8周MES为0或1的患者中,50/310(16%)直肠出血评分≥1,162/310(52%)排便频率评分≥1。
- 第38周MES为0或1的患者中,18/363(5%)直肠出血评分≥1,141/363(39%)排便频率评分≥1。
- 第8周直肠出血和排便频率变化与MES变化的Spearman相关系数分别为0.39(95%CI 0.32-0.45)和0.34(95%CI 0.27-0.40)。
临床怎么用
- 临床评估轻中度UC活动度时,不应仅依赖排便频率,需结合直肠出血和内镜检查。
局限性
- 本研究为事后分析,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Little is known about the association between rectal bleeding and increased stool frequency with endoscopic findings in patients with mild to moderate ulcerative colitis (UC). We evaluated the associations between rectal bleeding or stool frequency and endoscopic remission in this population. METHODS: We performed a post-hoc analysis of data from a phase 3 non-inferiority trial of 817 adults with mild to moderate UC who received treatment with mesalazine. We obtained information on rectal bleeding, stool frequency, and Mayo endoscopic subscores (MESs) at weeks 0, 8, and 38. The sensitivity, specificity, and positive and negative predictive values with which rectal bleeding and stool frequency identified patients with MESs of 0 and/or 1 were calculated at weeks 8 and 38 of treatment. The associations between change in rectal bleeding and stool frequency and change in MES after treatment were quantified using the Spearman's rank correlation coefficient. RESULTS: Among patients with a MES of 0, 7/82 patients (9%) had a rectal bleeding score of 1 or more and 40/82 patients (49%) had a stool frequency score of 1 or more at week 8; at week 38, 6/167 patients (4%) had a rectal bleeding score of 1 or more and 63/167 patients (38%) had a stool frequency score of 1 or more. Among patients with MESs of 0 or 1, 50/310 patients (16%) had a rectal bleeding score of 1 or more and 162/310 patients (52%) had had a stool frequency score of 1 or more at week 8; at week 38, 18/363 patients (5%) had a rectal bleeding score of 1 or more and 141/363 patients (39%) had a stool frequency score of 1 or more. The Spearman rank correlation coefficients for change in rectal bleeding and stool frequency with change in MES at week 8 were 0.39 (95% CI, 0.32-0.45) and 0.34 (95% CI, 0.27-0.40), respectively. In patients with reduced MESs at week 8, 39/389 patients (10%) had unchanged or worsening rectal bleeding and 81/389 patients (21%) had unchanged or increasing stool frequencies. CONCLUSIONS: In a post-hoc analysis of data from a phase 3 trial of adults with mild to moderate UC treated with mesalazine, we found absence of rectal bleeding to identify patients in endoscopic remission. However, many patients in remission still have increased stool frequency, indicating that it may not be a sensitive marker of disease activity in patients with mild to moderate UC.
引用
- Ma C, Sandborn WJ, D'Haens GR, et al. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019. PMID: 31546056. doi:10.1016/j.cgh.2019.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。